Articles

The incidence of heart failure and cardiomyopathy were significantly increased in women with breast cancer treated with trastuzumab either alone or in combination with anthracycline-based chemotherapy, according to the results of a recent large, population-based, retrospective cohort study. Read More ›

The US Food and Drug Administration (FDA) approved regorafenib (Stivarga, Bayer HealthCare Pharmaceuticals, Inc.) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemo­therapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib approval was granted on September 27, 2012. Read More ›

On October 4, 2012, the FDA and the US Centers for Disease Control and Prevention (CDC) recommended that all healthcare professionals cease use and remove from pharmaceutical inventory any product produced by the New England Com­pounding Center (NECC). Read More ›

The American Society of Clini­cal Oncology 2012 Breast Can­cer Symposium, held September 13-15 in San Francisco, California, offered all members of the cancer team an upfront view of new data and an opportunity for one-on-one interaction with experts. The following are a few research items of interest to oncology pharmacists. Read More ›

A new study further confirms racial disparities in the quality of communication between physicians and patients. Read More ›

Women diagnosed with aggressive breast cancer are more apt to receive adjuvant chemotherapy, but at the expense of completing locoregional radiation therapy. Read More ›

Public health recommendations regarding diet and lifestyle to prevent heart disease and diabetes may also decrease a man’s likelihood of dying of prostate cancer. Read More ›

By combining a cancer drug with a medication for erectile dysfunction and including a third therapy for heart transplants, researchers were able to kill cancer cells and protect the heart from damage. Read More ›

Hispanic breast cancer survivors who believed their English-language proficiency to be limited were less likely to rate their own health as good, very good, or excellent. Read More ›